TransCode Reports 71.4% Stable Disease Rate in Phase 1a TTX-MC138 Trial
RNAZ is trading near its 52-week low of $1.579 (0.9% above the low) on light trading volume (0.3× avg).
Summary
Updated Phase 1a data for TTX-MC138 show a 71.4% stable disease rate, three patients progression-free at 12 months, and no dose-limiting toxicities. The data support continued clinical evaluation of the lead candidate.
Key Events · Product Development and Regulatory · RNAZ
-
Phase 1a Data Shows 71.4% Stable Disease Rate
Among 14 efficacy-evaluable patients, 10 achieved stable disease as best overall response, with disease control rates of 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1.
-
Durable Responses in Heavily Pretreated Patients
Three patients remained progression-free at 12 months; six of 14 were progression-free at three months. Growth Modulation Index >1.3 was achieved in 40% of evaluable patients.
-
Favorable Safety Profile Confirmed
No dose-limiting toxicities were reported across all evaluated dose levels including 4.8 mg/kg, and no treatment-emergent adverse events led to discontinuation.
-
Biomarker Data Supports Antitumor Activity
Exploratory RNA-sequencing showed treatment-associated antitumor immune activation, including cytotoxic effector activity and enrichment of Type I interferon programs in stable disease patients.
Analysis · RNAZ · Life Sciences
Updated Phase 1a data for TransCode Therapeutics' lead candidate TTX-MC138 show a 71.4% stable disease rate in heavily pretreated advanced solid tumor patients, with three patients remaining progression-free at 12 months and no dose-limiting toxicities. The durability and breadth of disease control, combined with exploratory biomarker evidence of antitumor immune activation, strengthen the clinical rationale for the anti-miR-10b program. This matters because the company has a going-concern warning and cash runway only through year-end 2026 — positive clinical data is essential to attract the additional funding needed to continue development.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RNAZ was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.6M. The 52-week trading range was $1.58 to $20.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.